Medical cannabis isn’t an effective treatment for anxiety, depression or PTSD, new research shows
#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this evidence to counsel patients seeking cannabis for mental health conditions, as the research shows insufficient efficacy for anxiety, depression, and PTSD despite growing patient interest and availability. This finding helps providers make informed recommendations and may redirect patients toward evidence-based treatments like psychotherapy and medications with established efficacy for these conditions. Understanding the gap between patient expectations and actual clinical benefit is essential for shared decision-making and maintaining appropriate clinical standards of care.
A systematic review and meta-analysis of 54 randomized controlled trials found insufficient evidence that medical cannabis is effective for treating anxiety disorders, depression, or post-traumatic stress disorder, despite growing clinical interest in cannabinoid-based treatments for these conditions. The analysis revealed that most existing studies were small, heterogeneous in design, and often lacked rigorous outcome measures, limiting the ability to draw definitive conclusions about efficacy. Current evidence does not support recommending cannabis as a first-line or adjunctive treatment for these common psychiatric conditions, where established psychopharmacological and psychotherapeutic interventions remain the standard of care. Clinicians should counsel patients seeking cannabis for anxiety, depression, or PTSD that robust clinical evidence does not yet support such use and should discuss evidence-based alternatives. Until larger, well-designed trials demonstrate clear benefit and establish optimal dosing and cannabinoid ratios, cannabis should not be positioned as an effective psychiatric treatment despite patient interest and jurisdictional legalization.
“What this research tells us is that we’ve been operating on hope rather than evidence in this space, and patients deserve better than that. I still see cannabis help some anxious or depressed patients, but it’s often because of placebo, improved sleep, or reduced alcohol use rather than the cannabinoids themselves, and I’m now more direct about that distinction in clinical conversations.”
? While this systematic review finding of insufficient evidence for cannabis efficacy in anxiety, depression, and PTSD may seem definitive, clinicians should recognize that “no evidence of effect” differs from “evidence of no effect,” and the cannabis landscape remains methodologically challenging due to variability in cannabinoid compositions, dosing regimens, routes of administration, and patient populations across existing trials. Many patients self-report symptom relief, which may reflect placebo response, symptom fluctuation, concurrent treatments, or genuine but unmeasured biological mechanisms—a distinction that matters for the therapeutic relationship and shared decision-making. The absence of strong evidence in randomized trials also does not preclude potential benefit in specific subpopulations or therapeutic contexts that smaller or lower-quality studies may have captured. Given ongoing legalization and patient interest, practitioners should be prepared to discuss both the current evidence base and individual risk-benefit considerations, while encouraging patients to maintain established evidence
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
